Showing results for:
Palifermin is FDA approved to help prevent or lessen severe oral mucositis (inflammation of the mucous membrane of the mouth) in patients receiving certain types of blood cancer therapy.
Kepivance® Palifermin
Panobinostat (Farydak) is FDA approved for the treatment of patients with myeloma who have received at least two prior standard therapies, including bortezomib and an immunomodulatory agent. Panobinostat is to be used in combination with bortezomib, a type of chemotherapy, and dexamethasone, an anti-inflammatory medication.
Farydak® Panobinostat
Pegaspargase is FDA approved in combination with other chemotherapy medications to treat people who have acute lymphoblastic leukemia (ALL).
Oncaspar® PEG-L-asparaginase Pegaspargase
Pegfilgrastim is FDA approved toDecrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).Limitations of Use: Pegfilgrastim is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation
Neulasta® Pegfilgrastim G-CSF Fulphila™ * Pegfilgrastim-jmdb* Udenyca™ * Pegfilgrastim-cbqv* Ziextenzo™ * Pegfilgrastim-bmez * Nyvepria Pegfilgrastim-apgf* Fylnetra* Pegfilgrastim-pbbk* Stimufend®* Pegfilgrastim-fpgk*
Pembrolizumab is FDA approved for the treatment of:Adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL)Pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapyAdult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.Limitation of Use: Pembrolizumab is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Keytruda® Pembrolizumab
Pentostatin is FDA approved as a single-agent treatment for both untreated and alfa-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia (abnormally low white blood count), thrombocytopenia (reduced platelet count), or disease-related symptoms.
Nipent® Pentostatin
Pirtobrutinib is indicated for the treatment ofAdult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Pirtobrutinib Jaypirca®
Plerixafor injection is FDA approved for use along with a granulocyte colony-stimulating factor (G-CSF) medication in preparation for an autologous stem cell transplant in patients with non-Hodgkin lymphoma or myeloma. Plerixafor injection works by causing certain blood cells to move from the bone marrow to the blood so that they can be removed for transplantation.
Mozobil® Plerixafor
Polatuzumab vedotin-piiq is FDA approvedIn combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater.In combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies.
Polivy® Polatuzumab vedotin-piiq
Pomalidomide is FDA approved to treat people with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.
Pomalyst® Pomalidomide
Ponatinib is FDA approved for the treatment of adult patients with:Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Newly diagnosed Ph+ ALL, in combination with chemotherapy.This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.Chronic Myeloid Leukemia (CML)Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors.Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated.T315I-positive CML (chronic phase, accelerated phase, or blast phase).Limitations of Use: ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.
Iclusig® Ponatinib
Pralatrexate is FDA approved to treat people who have relapsed or refractory peripheral T-cell lymphoma. It is being studied to treat people who have other forms of lymphoma including diffuse large B-cell lymphoma.
Folotyn® Pralatrexate
Procarbazine is FDA approved with other anticancer drugs for the treatment of stage III and IV Hodgkin lymphoma. Procarbazine is used as part of the MOPP (mechlorethamine, Oncovin® [vincristine], procarbazine, prednisone) regimen. This medicine may cause a temporary loss of hair in some people. After treatment with procarbazine has ended, normal hair growth should return.
Matulane® Procarbazine
Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.
Quizartinib Vanflyta®
Rasburicase is FDA approved for the initial management of plasma uric acid levels in patients with leukemia, lymphoma and solid tumors who are receiving certain types of anticancer therapy expected to result in elevated plasma uric acid.
Elitek® Rasburicase
Remestemcel-L-rknd is indicated for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.
Ryoncil® Remestemcel-L-rknd
Revumenib is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
Revumenib Revuforj®
is FDA approved for the treatment of:Adult patients with non-Hodgkin lymphoma (NHL)Relapsed or refractory, low grade or follicular, CD20-positive Bcell NHL as a single agent.Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy.Non-progressing (including stable disease), low-grade, CD20- positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.Adult patients with chronic lymphocytic leukemia (CLL)Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
Rituxan® Rituximab Truxima® * Rituximab-abbs* Ruxience™ * Rituximab-pvvr* Riabni Rituximab-arrx*
Rituximab and hyaluronidase human
Rituximab and hyaluronidase human is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:Follicular Lymphoma (FL)Relapsed or refractory, follicular lymphoma as a single agentPreviously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single agent maintenance therapyNon-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapyDiffuse Large B-cell Lymphoma (DLBCL) Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimensChronic Lymphocytic Leukemia (CLL) Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC)Limitations of Use:Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion.
Rituxan Hycela® Rituximab and hyaluronidase human
Romidepsin is FDA approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy and treatment of patients with peripheral T-cell lymphoma (PTCL) who have received at least one prior therapy.
Istodax® Romidepsin
Ruxolitinib is FDA approved for treatment of Intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adultsPolycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyureaSteroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and olderChronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Jakafi® Ruxolitinib
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
super fancy brand name
Sargramostim is FDA approvedTo shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML).For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patients. For the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation in adult and pediatric patients 2 years of age and older.For the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older.For treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older.To increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).
Leukine ® GM-CSF Sargramostim
Selinexor is FDA approvedIn combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapyIn combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibodyFor the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.These indications are approved under accelerated approval based on response rate. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.
Xpovio® Selinexor
Tafasitamab-cxix is approved in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Monjuvi® Tafasitamab-cxix
Tagraxofusp-erzs is FDA approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older.
Elzonris™ Tagraxofusp-erzs
Talquetamab-tgvs is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Talquetamab-tgvs Talvey™
Tazemetostat is a methyltransferase inhibitor indicated for the treatment of:Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies.Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Tazverik™ Tazemetostat
Tecvayli™ (teclistamab‑cqyv) is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Tecvayli™ Teclistamab-cqyv
Teniposide is FDA approved along with other medicines as induction therapy to treat people who have refractory childhood acute lymphoblastic leukemia, non-Hodgkin lymphoma and other types of cancer. This medicine often causes a temporary loss of hair. After treatment with teniposide has ended, normal hair growth should return.
Vumon® VM-26 Teniposide
Thalidomide is FDA approved in combination with dexamethasone to treat patients with newly diagnosed myeloma. It is being studied to treat patients with myelodysplastic syndromes (MDS).
Thalomid® Thalidomide
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment ofPatients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.Limitation of Use: Kymriah is not indicated for treatment of patients with primary central nervous system lymphomaAdult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Kymriah® Tisagenlecleucel
Tocilizumab is approved for the treatment of adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS).CRS, which is caused by an overactive immune response, has been identified as a potentially severe and life-threatening side effect of CAR T cell therapy for certain cancers.
Actemra® Tocilizumab
Topotecan is an FDA-approved cancer drug that is used to treat people who have certain types of cancer including acute myeloid leukemia and acute lymphoblastic leukemia. This drug may cause a temporary loss of hair in some people. After treatment with topotecan has ended, normal hair growth should return.
Hycamtin® Topotecan
Tretinoin is an FDA-approved drug that is used to induce remission in patients who have acute promyelocytic leukemia (APL, also known as "M3 AML"), a type of acute myeloid leukemia (AML), with the t(15;17) translocation and/or the presence of the PML-RARa gene and who are intolerant of, refractory to, or have relapsed from anthracycline-based chemotherapy.
Vesanoid® ATRA Tretinoin All-trans retinoic acid (ATRA)
Vemurafenib (Zelboraf®) is FDA approved for the treatment of patients with Erdheim-Chester Disease (ECD) with BRAF V600 mutation.
Zelboraf® Vemurafenib
Venetoclax is FDA approved For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Venclexta® Venetoclax
Vinblastine is an FDA-approved chemotherapy agent that is used to treat people who have acute leukemia. It is sometimes used to treat other types of cancer including lymphoma.
Velban® Vinblastine